Interim Analysis of a Study Exploring Indoximod/Pembrolizumab Combo in Melanoma


Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses an interim analysis of the phase II clinical trial investigating the IDO pathway inhibitor indoximod in combination with pembrolizumab (Keytruda) for patients with advanced melanoma. 

Related Videos
Related Content